Lee Taebum, Park Cheol-Keun, Ha Sang Yun
Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Anatomic Pathology Reference Lab, Seegene Medical Foundation, Seoul, Republic of Korea.
Anticancer Res. 2019 Jun;39(6):3025-3031. doi: 10.21873/anticanres.13435.
BACKGROUND/AIM: apelin and apelin receptor (APJR) are involved in the regulation of angiogenesis, and their high expression is related to poor outcomes in several cancer types. Recently, several positive results on APJR antagonists in cancer treatment have been reported at the preclinical level. The aim of this study was to evaluate the prognostic effect of APJR expression on hepatocellular carcinoma (HCC) survival.
We evaluated APJR expression in 288 curatively resected HCCs using immunohistochemistry and investigated the correlation with clinicopathological features.
High APJR expression was significantly associated with the presence of microvascular invasion (p<0.001), intrahepatic metastasis (p=0.004), and early recurrence (p=0.029). The high-expression group showed shorter recurrence-free survival (p<0.001) and overall survival (p=0.001) than the low-expression group. In multivariate analysis, high APJR expression was an independent predictor of shorter recurrence-free survival (Hazard Ratio 1.49; 95% confidence interval 1.08-2.05, p=0.016).
We described-high APJR expression and its prognostic effect in HCC. Emerging target agents may be applicable in patients with HCC and high APJR expression.
背景/目的:apelin和apelin受体(APJR)参与血管生成的调节,其高表达与几种癌症类型的不良预后相关。最近,在临床前水平上报道了APJR拮抗剂在癌症治疗中的一些积极结果。本研究的目的是评估APJR表达对肝细胞癌(HCC)生存的预后影响。
我们使用免疫组织化学评估了288例根治性切除的HCC中APJR的表达,并研究了其与临床病理特征的相关性。
APJR高表达与微血管侵犯(p<0.001)、肝内转移(p=0.004)和早期复发(p=0.029)显著相关。高表达组的无复发生存期(p<0.001)和总生存期(p=0.001)均短于低表达组。在多变量分析中,APJR高表达是无复发生存期较短的独立预测因素(风险比1.49;95%置信区间1.08-2.05,p=0.016)。
我们描述了HCC中APJR的高表达及其预后影响。新兴的靶向药物可能适用于APJR高表达的HCC患者。